The novel PARP1 degrader NN3 circumvents PARP inhibitor resistance by selectively inducing ferroptosis in p53-positive (wild-type p53 or missense mutant p53) breast cancer cells through downregulating the solute carrier family 7 member 11 (SLC7A11) pathway (Li et al., 2022). Here, TP53 is linked to breast cancer.